Compare Abeona Therapeutics Inc (ABEO) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Roundhill Magnificent Seven ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Roundhill Magnificent Seven ETF trades at $65.85. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | MAGS | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $70.94 |
52-Week Low | $4.17 | $55.02 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MAGS (Roundhill Magnificent Seven ETF) trades at $66.28, up 1.81% on the day, with a bullish technical signal driven by moving averages. The ETF holds seven mega-cap tech stocks equally weighted, rebalanced quarterly. Recent news highlights AI-driven market broadening and MAGS's historical outperformance, though 2026 has seen volatility with a drop from YTD highs near $71. RSI_6 at 72.47 suggests short-term overbought conditions.
Outlook: MAGS offers concentrated exposure to leading tech innovators with strong long-term growth potential, but faces risks from high concentration, valuation concerns, and macroeconomic sensitivity. Near-term resistance at $67–68 may cap gains unless earnings momentum accelerates. Diversification benefits are limited due to single-sector focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
